The Effect of Tolterodine and Oxybutyninin on Nocturia in Patients with Benign Prostatic Hyperplasia.
- Author:
Jung Dam GIM
1
;
Young Jin SEO
;
Kyung Seop LEE
;
Ki Ho KIM
Author Information
1. Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea. honda400@dreamwiz.com
- Publication Type:Original Article
- Keywords:
Nocturia;
Tolterodine;
Oxybutynin
- MeSH:
Dizziness;
Headache;
Humans;
Mouth;
Nocturia*;
Prostatic Hyperplasia*;
Surveys and Questionnaires;
Urinary Bladder;
Tolterodine Tartrate
- From:Journal of the Korean Continence Society
2009;13(1):23-29
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Nocturia has been one of the most bothersome symptoms in benign prostatic hyperplasia (BPH) patients. Therefore, the authors evaluated the effect of tolterodine and oxybutyninin on nocturia in BPH patients. MATERIALS AND METHODS: From September 2006 to March 2007, 82 patients who presented over than 2 in nocturnal bladder capacity index (NCBI) in spite of having alpha blockers for 6 months were enrolled. Group I (n=38) took alpha blocker with tolterodine, group II (n=44) took alpha blocker with oxybutynin. The number of their nocturia episodes was separately evaluated by the time before and after the medication. The complications were assessed using a questionnaire. RESULTS: The number of nocturia episodes decreased by at least 1 in 68.4% (26/38), 84.1% (37/44) of patients in group I, II, respectively, and decreased by 2 or more, 1 and were unchanged or increased were 36.8, 31.6, 31.6% in group I patients and 45.5, 38.6, 15.9% in group II patients, respectively. In baseline nocturia > or =6 group, the nocturia decreased by 1 or more in 66.7%, 77.8% in group I, II, respectively. Adverse events, including dry mouth, dizziness, headache, etc, occurred in 21.1% (8/38) in group I and 27.3% (12/44) in group II patients. The complications between two groups showed no significant differences. CONCLUSIONS: Alpha blockers with tolterodine or oxybutynin can be effectively combined as a treatment option for patients with BPH complaining of unresolved nocturia.
